Shattuck Labs, Inc., a Durham, North Carolina and Austin, Texas-based clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC™) platform to develop a novel class of biologic medicines for the treatment of cancer and autoimmune disease, closed a $118m Series B equity financing.
The round was led by Redmile Group with participation from Janus Henderson Investors, Fidelity Management & Research Company, LLC, EcoR1 Capital, Hatteras Venture Partners, Avidity Partners, Partner Fund Management, Emerson Collective, and Piper Sandler & Co., as well as participation from existing investors.
The company intends to use the funds for the continued clinical development of SL-172154 (SIRPα-Fc-CD40L), a wholly-owned fusion protein that combines CD47 inhibition with CD40 co-stimulation, and SL-279252 (PD1-Fc-OX40L), its lead PD1 asset being developed in collaboration with Takeda Pharmaceuticals. Shattuck anticipates adding another clinical program in 2021 and continuing the development of an innovative pipeline of compounds for the treatment of cancer and autoimmune disease.
Led by Taylor Schreiber, M.D., Ph.D., Chief Executive Officer, Shattuck is a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC™) platform, a novel class of dual function fusion proteins with applications in oncology and autoimmune disease. The company’s lead program, SL-279252 (PD1-Fc-OX40L), is being studied in a Phase I trial in collaboration with Takeda Pharmaceuticals. A second compound, SL-172154 (SIRPα-Fc-CD40L), will begin enrollment in a Phase I trial in 2020.